ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing innovative medical products for the treatment of proliferative diseases.  The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis.  ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.